Merck, one of the largest vaccine makers in the world, is entering the Covid-19 arena with an announcement on Tuesday it is developing two different vaccines for Covid-19 and is also licensing an oral drug that might treat the virus.
Merck is buying Vienna-based Themis, which is developing an experimental Covid-19 vaccine based on a measles vaccine that could begin human studies soon. It is also partnering with the nonprofit IAVI on the development of a vaccine related to Merck’s existing Ebola vaccine that could enter human studies later this year. And it is licensing an experimental drug from a small company called Ridgeback Biotherapeutics.
“We are committed to making a contribution to the eradication of Covid-19,” Roger Perlmutter, who heads Merck Research Laboratories, the company’s